DBV Technologies initiates study for the treatment of peanut allergies

DBV Technologies has announced the initiation of a Phase three study designed to evaluate the safety and efficacy of Viaskin Peanut 250g in children ages 4 to 11 with peanut allergies Read more

9 Dec 2015 16:31 News